Improved Cutaneous Genetic Immunization by Microneedle Array Delivery of an Adjuvanted Adenovirus Vaccine

Erdö́s, G.; Balmert, Stephen C.; Carey, Cara Donahue; Falo, Gabriel D.; Patel, Nikita; Zhang, Jiying; Gambotto, Andrea; Korkmaz, Emrullah; Falo, Louis D.

doi:10.1016/j.jid.2020.03.966

Cited by 22 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This method of sustained release may also be applied in vaccination. Another method to increase the dissolution rate is increasing the antigen loading in the microneedles [ 116 ].…”

Section: Vaccination Into the Dermal Compartment Without Needle Anmentioning

confidence: 99%

Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects

Hettinga

Carlisle

2020

Vaccines

View full text Add to dashboard Cite

In 2019, an ‘influenza pandemic’ and ‘vaccine hesitancy’ were listed as two of the top 10 challenges to global health by the WHO. The skin is a unique vaccination site, due to its immune-rich milieu, which is evolutionarily primed to respond to challenge, and its ability to induce both humoral and cellular immunity. Vaccination into this dermal compartment offers a way of addressing both of the challenges presented by the WHO, as well as opening up avenues for novel vaccine formulation and dose-sparing strategies to enter the clinic. This review will provide an overview of the diverse range of vaccination techniques available to target the dermal compartment, as well as their current state, challenges, and prospects, and touch upon the formulations that have been developed to maximally benefit from these new techniques. These include needle and syringe techniques, microneedles, DNA tattooing, jet and ballistic delivery, and skin permeabilization techniques, including thermal ablation, chemical enhancers, ablation, electroporation, iontophoresis, and sonophoresis.

show abstract

“…This method of sustained release may also be applied in vaccination. Another method to increase the dissolution rate is increasing the antigen loading in the microneedles [ 116 ].…”

Section: Vaccination Into the Dermal Compartment Without Needle Anmentioning

confidence: 99%

Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects

Hettinga

Carlisle

2020

Vaccines

View full text Add to dashboard Cite

show abstract

“… 147 A 1 month storage of MNs vaccine at 4 °C maintained the immunogenicity of Ad, where no significant loss in antibody responses was shown in mice studies. 147 Similar dissolving MNs are also being investigated to deliver the SARS-CoV-2 subunit spike protein (S1). 120 Potent virus-specific antibody responses were elicited in mice as early as 2 weeks after the immunization with MNs.…”

Section: Vaccine Delivery Devicesmentioning

confidence: 91%

Engineering Antiviral Vaccines

Zhou

Jiang

et al. 2020

ACS Nano

View full text Add to dashboard Cite

Despite the vital role of vaccines in fighting viral pathogens, effective vaccines are still unavailable for many infectious diseases. The importance of vaccines cannot be overstated during the outbreak of a pandemic, such as the coronavirus disease 2019 (COVID-19) pandemic. The understanding of genomics, structural biology, and innate/adaptive immunity have expanded the toolkits available for current vaccine development. However, sudden outbreaks and the requirement of population-level immunization still pose great challenges in today’s vaccine designs. Well-established vaccine development protocols from previous experiences are in place to guide the pipelines of vaccine development for emerging viral diseases. Nevertheless, vaccine development may follow different paradigms during a pandemic. For example, multiple vaccine candidates must be pushed into clinical trials simultaneously, and manufacturing capability must be scaled up in early stages. Factors from essential features of safety, efficacy, manufacturing, and distributions to administration approaches are taken into consideration based on advances in materials science and engineering technologies. In this review, we present recent advances in vaccine development by focusing on vaccine discovery, formulation, and delivery devices enabled by alternative administration approaches. We hope to shed light on developing better solutions for faster and better vaccine development strategies through the use of biomaterials, biomolecular engineering, nanotechnology, and microfabrication techniques.

show abstract

“…To further improve the quality of MAP-based skin-targeted vaccination, several chemical and biological adjuvants (also known as immune-enhancers) have also been evaluated in pre-clinical studies [ 195 , 270 , 289 , 290 , 319 , 320 , 322 , [345] , [346] , [347] , [348] , [349] , [350] , [351] , [352] ]. For instance, one study investigated the effects of two different TLR agonists (imiquimod, a TLR7 agonist, and polyinosinic:polycytidylic acid (poly(I:C)), a TLR3 agonist) on humoral and cell-mediated immune responses in mice immunized with coated MAPs loaded with influenza antigen [ 351 ].…”

Section: Microarray Patchesmentioning

confidence: 99%

“…While the effect of poly(I:C) on influenza-specific adaptive immune responses was negligible, imiquimod improved antigen-specific Th1 immunity, as evidenced by enhanced IgG2a antibodies and IFN-γ producing T cells, which provide protection against viral infectious diseases. On the other hand, a recent study evaluated the effect of poly(I:C) on immune responses elicited by skin vaccination of mice with dissolvable MAPs incorporating live adenoviral vectored antigen (OVA) and showed that poly(I:C), when co-delivered with adenovirus in the same MAP, improved antigen-specific cellular immunity [ 352 ]. Another adjuvant, monophosphoryl lipid A (MPLA), a TLR4 agonist, has been tested with coated and dissolvable MAPs against RSV and HIV, respectively, in mice [ 270 , 322 ].…”

Section: Microarray Patchesmentioning

confidence: 99%

Microarray patches enable the development of skin-targeted vaccines against COVID-19

Korkmaz

Balmert

Sumpter

et al. 2021

Advanced Drug Delivery Reviews

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic is a serious threat to global health and the global economy. The ongoing race to develop a safe and efficacious vaccine to prevent infection by SARS-CoV-2, the causative agent for COVID-19, highlights the importance of vaccination to combat infectious pathogens. The highly accessible cutaneous microenvironment is an ideal target for vaccination since the skin harbors a high density of antigen-presenting cells and immune accessory cells with broad innate immune functions. Microarray patches (MAPs) are an attractive intracutaneous biocargo delivery system that enables safe, reproducible, and controlled administration of vaccine components (antigens, with or without adjuvants) to defined skin microenvironments. This review describes the structure of the SARS-CoV-2 virus and relevant antigenic targets for vaccination, summarizes key concepts of skin immunobiology in the context of prophylactic immunization, and presents an overview of MAP-mediated cutaneous vaccine delivery. Concluding remarks on MAP-based skin immunization are provided to contribute to the rational development of safe and effective MAP-delivered vaccines against emerging infectious diseases, including COVID-19.

show abstract

Improved Cutaneous Genetic Immunization by Microneedle Array Delivery of an Adjuvanted Adenovirus Vaccine

Cited by 22 publications

References 18 publications

Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects

Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects

Engineering Antiviral Vaccines

Microarray patches enable the development of skin-targeted vaccines against COVID-19

Contact Info

Product

Resources

About